We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Restructuring Aims to Speed Approval of New Cancer Drugs
FDA Restructuring Aims to Speed Approval of New Cancer Drugs
September 12, 2011
The FDA has merged its drugs and biologics review units for cancer treatments, turning the unit’s three divisions into four and giving the office a new name: the Office of Hematology and Oncology Products (OHOP).